These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24218766)

  • 21. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
    Nobori T; Nomura F
    Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized medicine - the promised land: are we there yet?
    Li C
    Clin Genet; 2011 May; 79(5):403-12. PubMed ID: 21204795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacometabonomics, pharmacogenomics and personalized medicine.
    Guţiu IA; Andrieş A; Mircioiu C; Rădulescu F; Georgescu AM; Cioacă D
    Rom J Intern Med; 2010; 48(2):187-91. PubMed ID: 21428184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Companion diagnostics and reimbursement system].
    Tazawa Y
    Rinsho Byori; 2013 May; 61(5):435-42. PubMed ID: 23947184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine.
    Ku CS; Roukos DH
    Expert Rev Med Devices; 2013 Jan; 10(1):1-6. PubMed ID: 23278216
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequencing set to alter clinical landscape.
    Hayden EC
    Nature; 2012 Feb; 482(7385):288. PubMed ID: 22337027
    [No Abstract]   [Full Text] [Related]  

  • 27. [Personalized medicine and molecular targets of drugs].
    Nishiyama M
    Nihon Rinsho; 2010 Oct; 68(10):1917-22. PubMed ID: 20954340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
    Halim AB
    Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming regulatory and economic challenges facing pharmacogenomics.
    Cohen JP
    N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart failure and personalized medicine.
    Mestroni L; Merlo M; Taylor MR; Camerini F; Sinagra G
    J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):6-12. PubMed ID: 20814312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How will personalized medicine impact the practice of gastroenterology?
    Lee LA
    Clin Gastroenterol Hepatol; 2011 Apr; 9(4):305-7. PubMed ID: 21439491
    [No Abstract]   [Full Text] [Related]  

  • 32. Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis.
    Lejbkowicz I; Caspi O; Miller A
    Expert Rev Neurother; 2012 Mar; 12(3):343-52. PubMed ID: 22364333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Companion diagnostics: significances and issues in its clinical application].
    Miyachi H
    Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnosis, prognosis, prediction].
    Wildner M
    Gesundheitswesen; 2014 Apr; 76(4):185-6. PubMed ID: 24771037
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should direct-to-consumer personalized genomic medicine remain unregulated?: a rebuttal of the defenses.
    Valles SA
    Perspect Biol Med; 2012; 55(2):250-65. PubMed ID: 22643762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A piece in the puzzle of personalized medicine.
    Kroemer HK; Meyer zu Schwabedissen HE
    Clin Pharmacol Ther; 2010 Jan; 87(1):19-20. PubMed ID: 20019696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethical and legal aspects of oncogenomics.
    Stankov K; Draskovic D; Mikov M
    J BUON; 2012; 17(2):383-8. PubMed ID: 22740222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.